Molbio Diagnostics IPO Financials
MainboardListedUpdated · GMP, subscription and listing data refresh through the day.
Molbio Diagnostics IPO Details
Market capitalisation is the post-issue share count in the offer document’s capital structure (11,52,39,996 shares) multiplied by the upper end of the price band, ₹807. It is arithmetic on those two filed figures, not a valuation.
Molbio Diagnostics Financials ₹ in crore
| ₹ crore | 2024 | 2025 | 2026 |
|---|---|---|---|
| Revenue | ₹836.56 | ₹1,020.42 | ₹1,445.69 |
| Expenses | — | — | — |
| Net profit (PAT) | ₹83.54 | ₹138.58 | ₹164.14 |
| PAT margin | 10.0% | 13.6% | 11.4% |
| Total assets | ₹1,221.06 | ₹1,461.56 | ₹2,148.42 |
Molbio Diagnostics Shareholding before & after the IPO
The founding owners and their group entities.
Post-issue pattern as filed with the NSE. Pre-issue register from the RHP capital structure, cross-checked against exchange data. Pre-issue percentages are taken from the disclosure, never estimated.
Molbio Diagnostics Anchor Investors largest allocation first
| # | Anchor investor | Shares | % of book | ₹ Cr |
|---|---|---|---|---|
| 1 | GOLDMAN SACHS FUNDS - GOLDMAN SACHS INDIA EQUITY PORTFOLIO | 3,09,780 | 8.88% | 25.00 |
| 2 | NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA PHARMA FUND RCT-RPF | 2,47,842 | 7.11% | 20.00 |
| 3 | INTERNATIONAL FINANCE CORPORATION* | 2,47,842 | 7.11% | 20.00 |
| 4 | BLACKROCK GLOBAL FUNDS - INDIA FUND | 2,47,842 | 7.11% | 20.00 |
| 5 | MIRAE ASSET HEALTHCARE FUND MIRAHCFD | 2,47,842 | 7.11% | 20.00 |
| 6 | ICICI PRUDENTIAL QUALITY FUND | 1,85,886 | 5.33% | 15.00 |
| 7 | ICICI PRUDENTIAL EXPORTS AND SERVICES FUND | 1,48,698 | 4.26% | 12.00 |
| 8 | KOTAK CONTRA FUND | 1,44,576 | 4.15% | 11.67 |
| 9 | KOTAK MAHINDRA TRUSTEE CO LTD A/C KOTAK HEALTHCARE FUND | 1,44,576 | 4.15% | 11.67 |
| 10 | KOTAK MAHINDRA TRUSTEE CO LTD A/C KOTAK CONSUMPTION FUND | 1,44,558 | 4.14% | 11.67 |
| 11 | HDFC MUTUAL FUND - HDFC PHARMA AND HEALTHCARE FUND | 1,38,006 | 3.96% | 11.14 |
| 12 | MOTILAL OSWAL LARGE CAP FUND | 1,23,930 | 3.55% | 10.00 |
| 13 | TATA INDIA PHARMA & HEALTHCARE FUND | 1,23,930 | 3.55% | 10.00 |
| 14 | NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA INNOVATION FUND | 1,23,912 | 3.55% | 10.00 |
| 15 | HDFC VALUE FUND | 1,08,432 | 3.11% | 8.75 |
| 16 | HDFC MUTUAL FUND - HDFC INNOVATION FUND | 1,08,414 | 3.11% | 8.75 |
| 17 | EDELWEISS TRUSTEESHIP CO LTD AC - EDELWEISS MF AC - EDELWEISS | 92,934 | 2.66% | 7.50 |
| 18 | HDFC LIFE INSURANCE COMPANY LIMITED | 88,597 | 2.54% | 7.15 |
| 19 | BAJAJ LIFE INSURANCE LIMITED | 88,596 | 2.54% | 7.15 |
| 20 | WHITEOAK CAPITAL PHARMA AND HEALTHCARE FUND | 80,568 | 2.31% | 6.50 |
| 21 | HDFC MUTUAL FUND - HDFC MNC FUND | 78,858 | 2.26% | 6.36 |
| 22 | GOLDMAN SACHS ETF TRUST - GOLDMAN SACHS INDIA EQUITY ETF | 61,974 | 1.78% | 5.00 |
| 23 | WHITEOAK CAPITAL AGGRESSIVE HYBRID FUND | 43,362 | 1.24% | 3.50 |
| 24 | ISIF EQUITY LONG-SHORT FUND | 37,170 | 1.07% | 3.00 |
| 25 | AXIS MAX LIFE INSURANCE LIMITED A/C SUSTAINABLE EQUITY FUND - ULIF02505/10/21SUSTAINEQU104 | 35,104 | 1.01% | 2.83 |
| 26 | AXIS MAX LIFE INSURANCE LIMITED A/C - ULIF00225/06/04LIFEBALANC104 - BALANCED FUND | 33,367 | 0.96% | 2.69 |
| 27 | EDELWEISS TRUSTEESHIP CO LTD AC - EDELWEISS MF AC- EDELWEISS RECENTLY LISTED IPO FUND | 30,996 | 0.89% | 2.50 |
| 28 | AXIS MAX LIFE INSURANCE LIMITED PENSION MAXIMISER FUND (ULIF01715/02/13PENSMAXIMI104) | 11,401 | 0.33% | 0.92 |
| 29 | AXIS MAX LIFE INSURANCE LIMITED A/C UHG2S - INDIA CONSUMPTION OPPORTUNITIES FUND | 2,625 | 0.08% | 0.21 |
| 30 | AXIS MAX LIFE INSURANCE LIMITED A/C UMFPH - HIGH GROWTH PENSION FUND | 2,625 | 0.08% | 0.21 |
| 31 | AXIS MAX LIFE INSURANCE LIMITED A/C - ULGF00217/04/06GRATBALANC104 - GROUP GRATUITY BALANCED FUND | 1,750 | 0.05% | 0.14 |
| 32 | AXIS MAX LIFE INSURANCE LIMITED PENSION PRESERVER FUND(ULIF01815/02/13PENSPRESER104) | 862 | 0.02% | 0.07 |
| 33 | AXIS MAX LIFE INSURANCE LIMITED A/C - ULIF00625/11/05PENSBALANC104 - PENSION BALANCED FUND | 862 | 0.02% | 0.07 |
Ranked by size of allocation; every anchor in an issue pays the same price, so the ranking is the same whether read in shares, rupees or share of the book. Anchor investors are allotted shares one day before the issue opens, at a price fixed on that day, and are locked in afterwards (30 days for half the allocation, 90 days for the rest). Read straight from the company’s own Anchor Allocation intimation letter filed with the exchanges — names appear exactly as printed there. Percentages are the filer’s own and total the anchor portion, not the whole issue. View the filed letter
Molbio Diagnostics IPO Lot Size & Minimum Investment by investor category
| Application | Shares | Amount at ₹807 |
|---|---|---|
| Retail (min)1 lot | 18 | ₹14,526 |
| Retail (max)13 lots | 234 | ₹1,88,838 |
| sHNI (min)14 lots | 252 | ₹2,03,364 |
| bHNI (min)69 lots | 1,242 | ₹10,02,294 |
One lot is 18 shares, so a single application at the ₹807 cut-off costs ₹14,526. Retail applications are capped at ₹2,00,000, which is 13 lots for this issue. Amounts are shown at the upper band because applications are made at the cut-off price.
Molbio Diagnostics IPO Strengths & Risks as disclosed in the DRHP
How to check Molbio Diagnostics IPO allotment status
Allotment is decided and published by the issue’s registrar, not by the exchange and not by alphave. For Molbio Diagnostics Limited, the registrar is KFin Technologies Limited — allotment is finalised in the days between the issue closing on 12 Aug 2026 and listing on 17 Aug 2026.
Allotment and refund dates follow SEBI’s T+3 listing timeline in trading days and are tentative until the registrar and the exchange confirm them. alphave does not hold allotment results — only the registrar can show whether an application was allotted.
The registrar publishes allotment on its own portal: KFintech. Your bank will also show the blocked amount released if shares were not allotted.
Molbio Diagnostics IPO Financials FAQs
What is the revenue of Molbio Diagnostics?
Molbio Diagnostics Limited reported revenue of ₹1,445.69 crore in FY2026, as restated in its offer document. The table on this page shows each reported year.
Is Molbio Diagnostics profitable?
Molbio Diagnostics Limited reported a profit after tax of ₹164.14 crore in FY2026. Earlier years are in the table above.
Where do the Molbio Diagnostics IPO financials come from?
From the restated financial statements in the company's draft and final offer documents filed with SEBI and the exchange. alphave reports them as filed, in ₹ crore, and does not publish a valuation or a view on the issue.
Molbio Diagnostics IPO Registrar where allotment and refund queries go
The registrar processes the allotment and the refunds. Contact details are as printed in the offer document; the exchange and your broker cannot change an allotment.
How to Apply for the Molbio Diagnostics IPO ASBA and UPI, as SEBI sets them
- Apply through your broker’s IPO window or your bank’s net banking (ASBA). The money stays in your own account and is only blocked until allotment.
- Choose the number of lots and bid at the cut-off price. Retail applications are capped at ₹2,00,000; above that the bid moves to the non-institutional category.
- If you applied through a broker, approve the UPI mandate in your payment app. The mandate must be approved by 5 pm on the day after your bid, and by 5 pm on the closing day for bids made on the last day (12 Aug 2026).
- One application per PAN. A second application under the same PAN is rejected, and both may be.
- After allotment the blocked amount is released for shares not allotted. Allotment and refund queries go to the registrar, KFin Technologies Limited, not to the exchange or the broker.
What is GMP in an IPO?
Grey Market Premium is the price at which an unlisted IPO application or share changes hands informally, before the stock is listed on the exchange. It is quoted as a rupee figure over the issue price: a premium of ₹120 on a ₹807 upper band means the grey market is dealing at ₹927.
The grey market is an over-the-counter market between private dealers. It is not operated or supervised by NSE, BSE or SEBI, no trade is settled through a clearing corporation, and no dealer is obliged to publish or honour a quote. Figures are collected by third-party reporters and different sources routinely disagree, which is why a premium can move sharply within a day or vanish entirely once bidding closes.
Grey Market Premium is an unofficial, unregulated over-the-counter datapoint reported by third parties. It is not a price, a forecast, or an indication of listing gains, and is not investment advice.